Evan Melrose, Md, Mba

Biobeat is redefining the way hypertension is diagnosed and managed through a first-of-its-kind, FDA-cleared, cuffless 24-hour blood pressure monitoring platform that delivers accurate, reliable, and comfortable monitoring without disrupting daily life. Our mission is to ensure that all patients are effectively monitored and managed. By combining 24-hour blood pressure data from our wireless, non-invasive chest patch with patient-reported insights, Biobeat provides a complete view of the patient journey. Clinicians can identify trends, correlate symptoms with vital signs, and make confident, personalized treatment decisions. Biobeat’s clinically validated platform is setting a new standard in hypertension care, eliminating the discomfort of traditional cuff-based monitoring, reducing white coat syndrome, and replacing fragmented data with a clear, actionable picture of patient health.

Cameron Health is a medical device developer based in San Clemente, California, USA. Cameron Health has its European office, Cameron Health BV, in Arnhem, The Netherlands. The privately-held company's focus is on the development and manufacture of a new generation of implantable cardioverter-defibrillator (ICD) implanted completely subcutaneously, called a Subcutaneous Implantable Defibrillator (S-ICD®). Cameron Health's approach avoids implanting leads in or on the heart, which has been the usual procedure for cardiac devices. Instead, the Cameron ICD is entirely implanted outside the thoracic wall.

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC.

Imperative Care is a Silicon Valley-based medical technology company researching, developing and manufacturing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company is focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Follow Imperative Care Stroke, and Imperative Care Vascular for updates.

Biobeat is redefining the way hypertension is diagnosed and managed through a first-of-its-kind, FDA-cleared, cuffless 24-hour blood pressure monitoring platform that delivers accurate, reliable, and comfortable monitoring without disrupting daily life. Our mission is to ensure that all patients are effectively monitored and managed. By combining 24-hour blood pressure data from our wireless, non-invasive chest patch with patient-reported insights, Biobeat provides a complete view of the patient journey. Clinicians can identify trends, correlate symptoms with vital signs, and make confident, personalized treatment decisions. Biobeat’s clinically validated platform is setting a new standard in hypertension care, eliminating the discomfort of traditional cuff-based monitoring, reducing white coat syndrome, and replacing fragmented data with a clear, actionable picture of patient health.

Spindletop Capital focuses on healthcare investment opportunities. We strategically invest in companies; both within the region and nationally, where we can best leverage our knowledge, experience, and Texas resources to add value beyond capital. We maximize asymmetric risk adjusted returns through exclusive focus on commercial stage healthcare opportunities, mitigating much of the technical, regulatory, and financial risk.

Spindletop Capital focuses on healthcare investment opportunities. We strategically invest in companies; both within the region and nationally, where we can best leverage our knowledge, experience, and Texas resources to add value beyond capital. We maximize asymmetric risk adjusted returns through exclusive focus on commercial stage healthcare opportunities, mitigating much of the technical, regulatory, and financial risk.

Cameron Health is a medical device developer based in San Clemente, California, USA. Cameron Health has its European office, Cameron Health BV, in Arnhem, The Netherlands. The privately-held company's focus is on the development and manufacture of a new generation of implantable cardioverter-defibrillator (ICD) implanted completely subcutaneously, called a Subcutaneous Implantable Defibrillator (S-ICD®). Cameron Health's approach avoids implanting leads in or on the heart, which has been the usual procedure for cardiac devices. Instead, the Cameron ICD is entirely implanted outside the thoracic wall.